December 2024 Growth Companies With Strong Insider Ownership

As global markets continue to navigate a landscape marked by political shifts and economic data releases, major U.S. indexes have shown mixed results with growth stocks leading the charge, notably outperforming their value counterparts. In this environment of dispersed sector performance and heightened anticipation around central bank decisions, companies with strong insider ownership can offer unique insights into potential growth trajectories, as insiders often possess valuable knowledge about their firm's prospects and are more likely to align their interests with shareholders.

Top 10 Growth Companies With High Insider Ownership

Name	Insider Ownership	Earnings Growth
Seojin SystemLtd (KOSDAQ:A178320)	30.9%	39.9%
Archean Chemical Industries (NSEI:ACI)	22.9%	41.3%
SKS Technologies Group (ASX:SKS)	32.4%	24.8%
Medley (TSE:4480)	34%	31.7%
Pharma Mar (BME:PHM)	11.8%	56.2%
Plenti Group (ASX:PLT)	12.8%	120.1%
Fine M-TecLTD (KOSDAQ:A441270)	17.2%	131.1%
Credo Technology Group Holding (NasdaqGS:CRDO)	13.6%	65.9%
HANA Micron (KOSDAQ:A067310)	18.4%	110.9%
Findi (ASX:FND)	34.8%	112.9%

Click here to see the full list of 1501 stocks from our Fast Growing Companies With High Insider Ownership screener.

Let's dive into some prime choices out of the screener.

Meituan (SEHK:3690)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Meituan is a technology retail company operating in the People's Republic of China with a market cap of approximately HK$963.05 billion.

Operations: The company's revenue is primarily derived from its Core Local Commerce segment, which generated CN¥239.81 billion, and its New Initiatives segment, contributing CN¥82.99 billion.

Insider Ownership: 11.9%

Earnings Growth Forecast: 21.6% p.a.

Meituan's recent financial performance highlights its growth potential, with Q3 2024 sales increasing to CNY 93.58 billion and net income rising sharply to CNY 12.86 billion from the previous year. Despite being undervalued relative to its estimated fair value, insider activity shows more selling than buying recently. Earnings are projected to grow significantly at over 20% annually, outpacing the Hong Kong market's growth rate of 11.3%, though revenue growth is slower than desired at 13% per year.

• Delve into the full analysis future growth report here for a deeper understanding of Meituan.
• Our valuation report here indicates Meituan may be overvalued.

Zhejiang Leapmotor Technology (SEHK:9863)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Zhejiang Leapmotor Technology Co., Ltd. focuses on the research, development, production, and sale of energy vehicles in China with a market capitalization of approximately HK$37.23 billion.

Operations: The company's revenue is primarily derived from the production, research and development, and sales of new energy vehicles, totaling approximately CN¥19.78 billion.

Insider Ownership: 15.2%

Earnings Growth Forecast: 73.4% p.a.

Zhejiang Leapmotor Technology is trading significantly below its estimated fair value, with insiders purchasing more shares than selling in recent months. Revenue is forecast to grow at 35.6% annually, outpacing the Hong Kong market's growth rate of 7.8%. The company is expected to become profitable within three years, though its return on equity remains modest at a projected 16.2%. Recent amendments to increase registered capital reflect strategic adjustments for future expansion.

• Take a closer look at Zhejiang Leapmotor Technology's potential here in our earnings growth report.
• The valuation report we've compiled suggests that Zhejiang Leapmotor Technology's current price could be quite moderate.

Boji Medical TechnologyLtd (SZSE:300404)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Boji Medical Technology Co., Ltd. offers contract research services for drug and medical device R&D and production to pharmaceutical companies both in China and internationally, with a market cap of CN¥3.64 billion.

Operations: Boji Medical Technology Co., Ltd. generates revenue by providing specialized contract research services focused on the development and production of pharmaceuticals and medical devices for both domestic and international clients.

Insider Ownership: 37.7%

Earnings Growth Forecast: 39.2% p.a.

Boji Medical Technology Ltd. demonstrates strong growth potential with revenue increasing to CNY 556.15 million for the first nine months of 2024, up from CNY 358.78 million a year earlier, and net income rising to CNY 43.28 million from CNY 23.02 million. Despite large one-off items affecting earnings quality, future earnings are expected to grow significantly at 39.2% annually, surpassing market averages, while revenue is projected to increase by 24% per year.

• Click here to discover the nuances of Boji Medical TechnologyLtd with our detailed analytical future growth report.
• The analysis detailed in our Boji Medical TechnologyLtd valuation report hints at an inflated share price compared to its estimated value.

Where To Now?

• Get an in-depth perspective on all 1501 Fast Growing Companies With High Insider Ownership by using our screener here.
• Invested in any of these stocks? Simplify your portfolio management with Simply Wall St and stay ahead with our alerts for any critical updates on your stocks.
• Maximize your investment potential with Simply Wall St, the comprehensive app that offers global market insights for free.

Curious About Other Options?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com